Company news

Amgen Inc. news in 2026

Amgen Inc.'s news releases, calls and decks from 2026, newest first.

View company

Amgen announces webcast of 2026 third quarter financial results

October 28, 2026

Amgen announces 2026 fourth quarter dividend

October 27, 2026

Amgen to present new data across rare and other serious autoimmune diseases at ACR convergence 2026

October 27, 2026

NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care

October 27, 2026

Amgen appoints David W. Gibbs to board of directors

October 26, 2026

IMDELLTRA® in combination with IMFINZI® reduced risk of death by an unprecedented 58% in first-line extensive stage small cell lung cancer

October 24, 2026

Amgen to present at the european society of medical oncology congress 2026

October 20, 2026

TEZSPIRE® delivered histologic remission and symptom improvement in eosinophilic esophagitis

October 20, 2026

TEZSPIRE® delivered histologic remission and Symptom improvement in eosinophilic esophagitis

October 20, 2026

New twice-yearly maintenance dosing option for people living with generalized myasthenia gravis in Canada

October 13, 2026

Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease

September 23, 2026

Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease

September 22, 2026

FDA approves reduced monitoring time for first two doses of IMDELLTRA®

September 14, 2026

In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC

September 14, 2026

Amgen to present at the morgan stanley 24th annual global healthcare conference

September 9, 2026

IMDELLTRA® in combination with imfinzi® demonstrated landmark improvement in overall survival in first-line extensive stage small cell lung cancer

September 8, 2026

Amgen to present at the 2026 wells fargo healthcare conference

September 2, 2026

Amgen's Repatha® reduces risk of death in patients at high risk for a first heart attack or stroke

August 31, 2026

TEZSPIRE® demonstrates positive Phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

August 27, 2026

Amgen to open new science & innovation center in Genome Valley, Hyderabad

August 12, 2026

Amgen reports second quarter 2026 financial results

August 4, 2026

Amgen announces 2026 third quarter dividend

July 30, 2026

Positive CHMP opinion supports broader use of Amgen's Repatha® before a first heart attack or stroke

July 29, 2026

Amgen announces webcast of 2026 second quarter financial results

July 28, 2026

Statement on FDA Data Submission for TAVNEOS® (avacopan)

July 24, 2026

Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech

July 8, 2026

What a Landmark Real-World Study Reveals About Thyroid Eye Disease

June 22, 2026

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

June 7, 2026

Amgen presents new data across its cardiometabolic portfolio at American Diabetes Association 86th scientific sessions

June 7, 2026

Amgen to present at the goldman sachs 47th annual global healthcare conference

June 4, 2026

Amgen to present new data across rare autoimmune and inflammatory Diseases at EULAR 2026

June 3, 2026

Amgen: European commission approves amgen's imdylltra® for the treatment of extensive-stage small cell lung cancer

June 1, 2026

European Commission approves Amgen's IMDYLLTRA® for the treatment of extensive-stage small cell lung cancer

June 1, 2026

Approach to AI-Enabled Clinical Development

May 20, 2026

Amgen announces retirement of chief financial officer Peter Griffith

May 19, 2026

Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed

May 18, 2026

Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential

May 12, 2026

Procrit (Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 7, 2026

Amgen announces additional $300 million U.S. manufacturing investment, totaling nearly $2 billion over the last year

May 4, 2026

Blincyto (blinatumomab: Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 1, 2026

Amgen reports first quarter 2026 financial results

April 30, 2026

TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026

April 27, 2026

Amgen announces webcast of 2026 first quarter financial results

April 24, 2026

Amgen announces retirement of David M. Reese, executive vice president and Chief Technology Officer

April 22, 2026

Liver Failure: Amgen Continues Marketing Avacopan (Tavneos) in the United States

April 7, 2026

Amgen announces positive topline phase 3 results for subcutaneous TEPEZZA® in adults living with moderate-to-severe active thyroid eye disease

April 5, 2026

Global Familial Hypercholesterolemia Treatment Market Led by North America as Amgen and Novartis Expand Therapies

April 2, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

March 31, 2026

Repatha® cuts risk of first major cardiovascular events by 31% in high-risk patients without known significant atherosclerosis

March 27, 2026

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

March 12, 2026

Older news releases →

Calls in 2026

Decks in 2026